We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease ... Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Show more
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...
Announced Strategic Collaboration with HMNC Brain Health GmbH (HMNC) to Develop Tildacerfont for the Treatment of Major Depressive Disorder (MDD) Topline Data from CAHmelia-204 Study of...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...
ในใใซใผในใฎๆฒป้จ่ฌๅ่ฃใงใใใใซใใปใซใใฉใณใใจใHMNCใฎใณใณใใใชใณ่จบๆญใงใใ็ฌ่ชใฎใณใซใใใณ้บไผๅญ้ธๆใใผใซใ็ตใฟๅใใใฆใCRF 1ๅๅฎนไฝๆฎๆไฝ็จใซๅๅฟๆงใฎใใMDDๆฃ่ ใๆฒป็ ็ฌฌ2็ธๆฆๅฟตๅฎ่จผ่ฉฆ้จใฎๅฎไบ...
Kombiniert Spruce's Produktkandidat Tildacerfont mit HMNC's Begleitdiagnostikum, dem proprietรคren Cortibon Genetic Selection Tool, zur Behandlung von MDD-Patienten, die auf CRF...
Pairs Spruceโs Investigational Product Candidate, Tildacerfont, with HMNCโs Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF1...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0016 | 0.352889280988 | 0.4534 | 0.4699 | 0.425 | 424182 | 0.44011725 | CS |
4 | -0.0058 | -1.25868055556 | 0.4608 | 0.4847 | 0.42 | 504664 | 0.44823145 | CS |
12 | -0.0715 | -13.5802469136 | 0.5265 | 0.5649 | 0.41115 | 407518 | 0.46159225 | CS |
26 | -0.2846 | -38.4802595998 | 0.7396 | 0.87 | 0.41115 | 465824 | 0.58317236 | CS |
52 | -1.135 | -71.3836477987 | 1.59 | 5.95 | 0.41115 | 598619 | 1.26568388 | CS |
156 | -4.395 | -90.618556701 | 4.85 | 5.95 | 0.41115 | 708967 | 3.00382573 | CS |
260 | -16.545 | -97.3235294118 | 17 | 35.6 | 0.41115 | 546908 | 3.44277602 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions